Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro by Feelders, R.A. (Richard) et al.
Luteinizing Hormone (LH)-Responsive Cushing’s
Syndrome: The Demonstration of LH Receptor
Messenger Ribonucleic Acid in Hyperplastic Adrenal
Cells, which Respond to Chorionic Gonadotropin and
Serotonin Agonists in Vitro
RICHARD A. FEELDERS, STEVEN W. J. LAMBERTS, LEO J. HOFLAND,
PETER M. VAN KOETSVELD, MIRIAM VERHOEF-POST, AXEL P. N. THEMMEN, FRANK H. DE JONG,
H. JAAP BONJER, ADRIAN J. CLARK, AART-JAN VAN DER LELY, AND WOUTER W. DE HERDER
Departments of Internal Medicine and Endocrinology (R.A.F., S.W.J.L., L.J.H., P.M.v.K., M.V.-P., A.P.N.T., F.H.d.J.,
A.-J.v.d.L., W.W.d.H.) and Surgery (H.J.B.), Erasmus University Medical Center Rotterdam, 3015 GD Rotterdam, The
Netherlands; and Department of Endocrinology (A.J.C.), St. Bartholomew’s and the Royal London School of Medicine and
Dentistry, EC1A 7BE London, United Kingdom
In a substantial part of adrenal adenomas and hyperplasias
from patients with Cushing’s syndrome, cortisol production is
controlled by the expression of aberrant hormone receptors
on adrenocortical cells. We present in vivo and in vitro data of
two patients with a LH-responsive Cushing’s syndrome based
on ACTH-independent bilateral adrenal hyperplasia.
Patients 1 and 2 are women who presented with Cushing’s
syndrome and bilateral adrenal hyperplasia. Endocrine test-
ing demonstrated absence of cortisol diurnal rhythm, insuf-
ficient cortisol suppression after 1 mg dexamethasone orally,
and undetectable ACTH levels in both patients. Both patients
were treated by laparoscopic biadrenalectomy.
In in vivo testing, in patients 1 and 2, a profound cortisol rise
was found after administration of GnRH [change in cortisol
(F), 118 and 106%, respectively], human CG (F, 133 and 44%),
LH (F, 73 and 43%), ACTH (F, 89 and 181%), and the 5-
hydroxy-tryptamine receptor type 4 (5-HT4) agonists cisa-
pride (F, 141 and 148%) and metoclopramide (F, 189 and
95%).
In in vitro testing, adrenal cells from patient 2 responded,
in a dose-dependent fashion, with cortisol production after
exposure to human CG (F, 45%), cisapride (F, 68%), and
metoclopramide (F, 81%). ACTH induced cortisol production
by cells from both patients (F, 135 and 159%).
In receptor studies, LH receptor mRNA was demonstrated
in adrenal tissue of both patients but also in control adrenal
tissue of two patients with persisting pituitary-dependent
Cushing’s syndrome treated by biadrenalectomy. In neither
patient were mutations found in the ACTH receptor gene.
LH-responsive Cushing’s syndrome associated with bilat-
eral adrenal hyperplasia may result from aberrant (or possi-
bly increased) adrenal LH receptor expression. This variant is
further characterized by adrenal responsiveness to 5-HT4 re-
ceptor agonists, possibly pointing to an interaction between
LH and serotonin in the regulation of cortisol secretion. De-
spite the regulatory potential of LH and 5-HT4 receptor ago-
nists on cortisol production in our patients, their adrenals
seemed to be still sensitive to ACTH, both in vivo and in vitro.
(J Clin Endocrinol Metab 88: 230–237, 2003)
ENDOGENOUS CUSHING’S SYNDROME is tradition-ally divided into ACTH-dependent and ACTH-inde-
pendent variants. The spectrum of ACTH-independent
Cushing’s syndrome includes unilateral adrenal adenoma
and carcinoma and, rarely, bilateral macro- or micronodular
adrenal hyperplasia. Excess production of cortisol by adrenal
tumors or hyperplasias was previously considered to be au-
tonomous. However, in recent years, increasing evidence has
been obtained that cortisol secretion by a substantial part of
adrenal neo- or hyperplasias may be controlled by aberrant
hormone receptors (1). This involves the adrenal expression
of receptors (e.g. for catecholamines, TSH, vasopressin, and
gastric inhibitory peptide), which appear to be functionally
coupled to steroidogenesis.
Recently, Lacroix et al. (2) reported a female patient with
bilateral adrenal hyperplasia and ACTH-independent Cush-
ing’s syndrome, which presented clinically only during preg-
nancy and after the menopause. In this patient, cortisol
production in vivo was stimulated by LH, chorionic gonad-
otropin [human CG (hCG)], but also by agonists of the 5-
hydroxy-tryptamine type 4 (5-HT4) receptor, suggesting
aberrant adrenal expression of LH and 5-HT4 receptors.
However, this was not confirmed by in vitro studies.
We describe two female patients with bilateral adrenal
hyperplasia and ACTH-independent hypercortisolism who
also exhibited a profound cortisol response to LH, hCG, and
5-HT4 receptor agonists in vivo. Both patients were treated by
laparoscopic biadrenalectomy, allowing for receptor and in
vitro studies of hormone release. LH receptor mRNA was
demonstrated in adrenal tissue of both patients. This indi-
cates that in LH-responsive Cushing’s syndrome associated
with bilateral adrenal hyperplasia, cortisol production is con-
trolled via adrenal LH receptor expression.
Abbreviations: APC, Adenomatous polyposis coli; F, change in cor-
tisol; hCG, human CG; 5-HT4, 5-hydroxy-tryptamine receptor type 4;
PRL, prolactin; RNase, ribonuclease.
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Subjects and Methods
Case reports
Patient 1. The first patient is a 60-yr-old postmenopausal woman who
was admitted for analysis of bilateral adrenal hyperplasia. During an
urological evaluation for transient hematuria, abdominal computed to-
mography revealed bilaterally enlarged adrenals (left adrenal, 5 cm;
right adrenal, 3.5 cm). Clinical symptoms suggestive of hypercortisolism
included easy bruisability, muscle weakness, and depression. The med-
ical history included a hysterectomy. No abnormal weight gain had
occurred during two previous pregnancies. She had not been treated
with glucocorticoids. She used estrogen-replacement therapy. There was
no family history of endocrine disorders. At physical examination, she
had moderate central obesity, mild plethora, and skin atrophy with
several ecchymoses. The patient’s height was 1.67 m, and her weight was
68 kg. Blood pressure was 130/85 mm Hg. Endocrine evaluation (see
Results) revealed ACTH-independent hypercortisolism, with stimula-
tion of cortisol production after the administration of GnRH, hCG, LH,
cisapride, metoclopramide, and ACTH, but no response to FSH. A trial
with leuprolide acetate was proposed to the patient, but she insisted on
having an operation. Subsequently, the patient was treated by laparo-
scopic biadrenalectomy. Histological examination of adrenal tissue
showed micro- and macronodular hyperplasia of the adrenal cortex,
with a predominance of macronodules. The size of the nodules varied
from 2 mm to 2 cm, and there was no internodular atrophy. Postoper-
atively, replacement therapy was started with hydrocortisone, 9-fluor-
hydrocortisone, and dehydroepiandrosterone. Clinical symptomatol-
ogy of Cushing’s syndrome fully resolved after several months.
Patient 2. The second patient is a 40-yr-old premenopausal woman who
presented with a 12-month history of easy bruisability, proximal muscle
weakness, and hypertension. In the past 10 yr, she had recurrent epi-
sodes of depression and weight gain of approximately 40 kg. In the
second and fourth year of this period, the patient had two pregnancies
without an abnormal weight gain. She had undergone a hysterectomy,
2 yr before admission. There was no family history of endocrine ab-
normalities. The patient’s height was 1.59 m, and her weight was 83 kg.
Blood pressure was 140/90 mm Hg. She had mild facial plethora, a
cushingoid fat distribution with a buffalo hump, supraclavicular fat
pads, and central obesity but no acne, hirsutism, or abdominal striae.
Endocrine testing (see Results) demonstrated ACTH-independent hy-
percortisolemia. An abdominal computed tomography scan showed
bilateral adrenal hyperplasia (left adrenal, 3 cm; right adrenal, 5 cm).
Additional tests demonstrated a marked cortisol response after admin-
istration of GnRH, hCG, LH, cisapride, and metoclopramide as well as
ACTH, but no response to FSH. The patient refused a trial with leu-
prolide acetate and was therefore treated by laparoscopic biadrenalec-
tomy, followed by replacement therapy with hydrocortisone, 9-fluor-
hydrocortisone, and dehydroepiandrosterone. Histological examination
of the adrenal glands showed micro- and macronodular hyperplasia of
the adrenal cortex, with the size of the nodules varying from 2 mm to
3 cm. There was no internodular atrophy. Her clinical picture of Cush-
ing’s syndrome disappeared within several months thereafter. Apart
from this diagnosis, this patient was diagnosed with familial adenoma-
tous polyposis, associated with a mutation in the adenomatous polyp-
osis coli (APC) gene, with localization of adenocarcinomas in the du-
odenum, cecum, and rectum. The association of familial adenomatous
polyposis, adrenal neoplasia, and APC mutation has been described
previously (3). After the biadrenalectomy, she underwent a Whipple
procedure and a total colectomy.
Control patients. Hyperplastic adrenal tissue, serving as control tissue,
was obtained from two female patients of 45 and 56 yr old, respectively,
with persistent Cushing’s disease after pituitary surgery and radiother-
apy, who were treated by laparoscopic biadrenalectomy.
Procedure
All studies were performed according to the rules of the hospital
medical ethics committee. Informed consent was obtained from all
patients.
Assays. Plasma cortisol (reference value, 200–800 nm), urinary cortisol
(determined in unextracted urine; upper limit, 850 nmol/24 h), and
plasma ACTH-(1–39) concentrations (detection limit, 10 ng/liter) were
measured by a fluorescent immunoassay (Diagnostic Products, Los An-
geles, CA). Plasma LH (premenopausal reference value, 1–50 IU/liter;
postmenopausal, 15–90 IU/liter) and FSH (premenopausal, 1–25 IU/
liter; postmenopausal, 35–150 IU/liter) concentrations were determined
by an immunofluorometric assay (Diagnostic Products). Plasma estra-
diol concentrations (premenopausal, 50–800 pm; postmenopausal,100
pm) were measured by a RIA (Diagnostic Products).
Cell preparation and incubation studies. Directly after laparoscopic re-
moval, adrenal cortical tissue of the major part of the adrenals was
minced into small pieces and dissociated with collagenase (type I; Sigma,
St. Louis, MO) as described previously (4, 5). Cell viability was deter-
mined by trypan blue staining and was more than 80%. Subsequently,
the cells were resuspended in incubation medium (DMEM with 0.2%
BSA) and incubated with and without test substances during 2 or 24 h.
These incubations were performed in quadruplicate using 500,000 cells/
ml. After 2- or 24-h incubation, 0.5 ml distilled water was added to each
tube, and the resulting suspension was stored at –20 C until measure-
ment of hormone concentrations, as described previously (4). The 2-h
incubations were performed with the following substances: ACTH-(1–
24) (Synacthen; Novartis, Basel, Switzerland; concentrations: 32, 64, 132,
and 615 pg/ml), forskolin in a concentration of 1 m, recombinant
human GnRH (gonadorelin; Aventis Pharma, Frankfurt, Germany; 0.1
and 1 m), recombinant human LH (Serono, Rome, Italy; 10, 50, 100, and
1,000 mIU/ml), purified hCG (Organon, Oss, The Netherlands; 10, 50,
100, and 1,000 mIU/ml), recombinant human FSH (Serono, Italy; 10, 50,
and 100 mIU/ml), cisapride (Janssen Pharmaceuticals, Cilag, The Neth-
erlands; 0.01, 0.1, and 1 m), metoclopramide (0.1, 1, and 10 m), and
the combinations of ACTH (64 pg/ml) with: GnRH (1 m), LH (100
mIU/ml), hCG (100 mIU/ml), cisapride (0.1 m), and metoclopramide
(1 m). The 24-h incubations were performed with ACTH (615 pg/ml),
forskolin (1m), LH (100 mIU/ml), hCG (100 mIU/ml), metoclopramide
(1m), and (in patient 2) also with estradiol (Steroloids, Wilton, NH; 0.01
and 0.1 m), activin A (25 ng/ml), and inhibin A (25 ng/ml).
Detection of LH receptor mRNA. After laparoscopic biadrenalectomy, ad-
renal specimens were frozen immediately in liquid nitrogen and stored
at –80 C. Total RNA was isolated from adrenal specimens using an
LiCl-urea protocol (6). For detection of LH receptor mRNA expression,
using a ribonuclease (RNase) protection assay, a 300-bp RNA probe was
used, transcribed from a 300-bp (bp, 1100–1400) blunted Bsu36I-XbaI
fragment that was cloned in the SmaI-XbaI sites of the pBluescript vector.
This probe identifies part of exon 11 of the LH receptor gene. Other
probes corresponding to exons 1–10 of the LH receptor were also em-
ployed but were less efficient (lower signal; results not shown). As
control for RNA isolation, expression of -actin mRNA was used as
described before (7). As positive control for the RNase protection assay,
RNA isolated from a stable cell line expressing the human LH receptor
was used. HEK293 cells were transfected with the expression vector
pSG5, containing human LH receptor cDNA (8) in combination with the
cAMP-response reporter pCRE6Lux (8, 9). Several stable lines were
obtained with various levels of LH receptor expression and response to
hCG. Clone K15 was selected, because this clone showed low LH re-
ceptor mRNA expression, as compared with the other clones combined
with a solid response to hCG (Dr. A. van Marle, unpublished results).
After RNase expression, the bands were quantified using a Phospho-
imager and ImageQuant software package (Molecular Dynamics, Inc./
B&L Systems, Zoetermeer, The Netherlands). mRNA expression is de-
picted as the ratio of the human LH receptor over -actin.
Characterization of the ACTH receptor gene sequence. Leukocyte DNA was
prepared from both patients by standard procedures. Genomic DNA
was amplified and sequenced using a Big dye protocol (Applied Bio-
systems, Warrington, UK) analyzed on an ABI 377 automated DNA
sequencer. PCR primers were described previously (10).
Statistics. The effects of various test substances on in vitro cortisol pro-
duction by cultured adrenal cells were tested by ANOVA, followed by
Newman-Keuls test.
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Results
Hypercortisolism
Patient 1. The initial endocrine evaluation revealed an absent
cortisol diurnal rhythm: at 0800 h, 339 nm; at 1700 h, 352 nm;
at 2200 h, 363 nm; and at midnight, 441 nm. The patient’s
cortisoluria varied from 550–630 nmol/24 h. The cortisol
concentration at 0800 h, after oral administration of 1 mg
dexamethasone at 2200 h, was 336 nm (suppression cutoff
value,150 nm) and at 7 h after 7 mg dexamethasone iv (11),
370 nm (no decrease). Basal ACTH concentrations were be-
low the detection limit of 10 ng/liter.
Patient 2. Endocrine evaluation demonstrated absence of cor-
tisol diurnal rhythm: at 0800 h, 365 nm; at 1700 h, 402 nm; and
at 2200 h, 404 nm. Cortisoluria was increased and varied
between 900-1800 nmol/24 h. Plasma cortisol concentrations
were not suppressed after the oral administration of 1 mg
dexamethasone (cortisol at 0800 h, 469 nm), or by iv admin-
istration of 7 mg dexamethasone (cortisol after 7 h, 630 nm).
Basal ACTH concentrations were undetectable. Administra-
tion of 1 g/kg human CRH iv was not, followed by a
response of plasma ACTH and cortisol concentrations.
Effects of GnRH, hCG, LH, and FSH
Data are shown in Table 1 and Figs. 1 and 2.
Patient 1. Administration of 100 g GnRH iv resulted in a
rapid increase in LH levels from 11.4 U/liter to peak levels
after 60 min, directly followed by an increase in cortisol
concentrations from 444 nm to peak levels after 150 min (Fig.
1A). FSH levels rose more slowly from 26.4 to 58.3 U/liter
after 150 min. Plasma estradiol concentrations, 633 pm at
baseline, did not change significantly after GnRH adminis-
tration. Administration of 10,000 U hCG im induced a com-
parable increase in plasma cortisol levels from 448 nm to peak
levels after 240 min (Fig. 1B). After administration of 300 U
LH im cortisol, concentrations rose from 181 nm to peak
levels after 30 min (Fig. 1C).
Patient 2. After administration of 100 g GnRH iv, cortisol
levels increased from 379 nm to peak levels after 90 min,
preceded by a rise in LH concentrations from 2.8 U/liter to
peak levels after 60 min (Fig. 2A). FSH concentrations in-
creased from 5.1 to 29.9 U/liter after 120 min. No change was
observed in plasma estradiol concentrations, 344 pm at base-
line, after GnRH administration. Administration of 10,000 U
hCG im resulted in an increase in plasma cortisol levels from
445 nm to peak levels after 240 min (Fig. 2B). After admin-
istration of 300 U LH im, cortisol concentrations rose from
332 nm to peak levels after 90 min (Fig. 2C). FSH adminis-
tration (300 U im) was not followed by a cortisol response in
either patient (data not shown). In both patients, ACTH
levels remained undetectable in all stimulation tests.
Effects of ACTH, cisapride, and metoclopramide
Patient 1. After the administration of 10 mg cisapride orally,
plasma cortisol levels increased from 572 nm to peak levels
after 180 min (Fig. 1E). Three hours after the administration
of cisapride, an ACTH stimulation test (250 g im) was
performed. Cortisol levels subsequently rose further, from
1400 to 3369 nm, after 120 min (Fig. 1D). The oral adminis-
tration of 10 mg metoclopramide was followed by an increase
in cortisol levels from 395 to 1140 nm (Fig. 1F).
Patient 2. Stimulation with 250 g synthetic ACTH im re-
sulted in a cortisol rise from 290 to 1234 nm after 90 min (Fig.
2D). Administration of cisapride and metoclopramide was
followed by increases in plasma cortisol levels from 357 to
885 nm (Fig. 2E) and from 278 to 543 nm (Fig. 2F), respec-
tively, after 120 min. Plasma ACTH levels were undetectable
in all stimulation tests in both patients.
Effects of other stimuli
Both patients were screened for the presence of other ab-
normal cortisol responses based on aberrant adrenal recep-
tors, according to the protocol of Lacroix et al. (1), including
serial measurements of ACTH and cortisol in the fed and
fasting state and a posture test (2 h, supine position), fol-
lowed by a 2-h ambulatory period, a standard mixed meal,
a 200-g TRH test, a 1-mg glucagon test, and a 10-IU arginine
vasopressin test. No abnormal cortisol responses were found
in these tests (data not shown).
In vitro studies
Two-hour incubation. Data are shown in Tables 2 and 3. Cul-
tured adrenocortical adenoma cells, obtained from patients
1 and 2 and control patients 1 and 2, produced 36 1.7, 91.5
1.1, 122.8  10.6, and 85.2  5.9 nmol cortisol/tube (mean 
sd), respectively, after 2 h. Incubation with ACTH stimulated
cortisol production in a dose-dependent fashion, to maxi-
mum values of 84.4  12.6, 236.8  4.1, 468.6  54.8, and
232.7  26.5 nmol/tube, respectively. Forskolin, as stimula-
tor of cAMP production, stimulated in vitro cortisol produc-
tion by the adrenal cells of all patients (Table 2). Cisapride
and metoclopramide had a dose-dependent effect on cortisol
production by cells obtained from patient 2 but no effect on
cortisol production by cells from patient 1 or the control
patients (Table 2). GnRH, LH, hCG, and FSH had no signif-
icant effect on cortisol production in patient 1 and the control
patients, whereas hCG stimulated cortisol production in pa-
tient 2 (Table 3). ACTH-stimulated cortisol production was
not potentiated by coincubation with GnRH, LH, hCG, cisa-
pride, or metoclopramide (data not shown).
TABLE 1. Peak plasma cortisol values, as percentage of baseline
values, in in vivo stimulation tests in two patients with LH-
responsive Cushing’s syndrome based on bilateral adrenal
hyperplasia
Stimulation test
Patient 1
(peak value as
% of baseline)
Patient 2
(peak value as
% of baseline)
GnRH (100 g iv) 218 206
hCG (10,000 U im) 233 144
LH (300 U im) 173 143
FSH (300 U im) 95 99
Cisapride (10 mg orally) 241 248
Metoclopramide (10 mg orally) 289 195
ACTH (250 g im) 189 281
232 J Clin Endocrinol Metab, January 2003, 88(1):230–237 Feelders et al. • LH-Responsive Cushing’s Syndrome
 on November 14, 2006 jcem.endojournals.orgDownloaded from 
Twenty-four-hour incubation. Incubation of cultured adrenal
cells during 24 h with the same panel of test substances had
no additive effect on cortisol production (data not shown).
The adrenal cell culture of patient 2 was also incubated with
estradiol, activin, and inhibin during 24 h, which had no
significant effect on in vitro cortisol production.
Receptor studies
LH receptor. Presence of LH receptor mRNA was demon-
strated in the hyperplastic adrenal tissue of patients 1 and 2,
as well as in hyperplastic adrenal tissue of both control pa-
tients with pituitary-dependent Cushing’s syndrome (Fig. 3).
LH receptor mRNA expression in adrenal tissue from both
the patients with LH-responsive Cushing’s syndrome and
the control patients was low, compared with the LH-recep-
tor-expressing K15 cell line that served as control. LH re-
ceptor mRNA expression was slightly higher in adrenal
tissue from the patients with LH-responsive Cushing’s syn-
drome, compared with adrenal tissue from the control
patients.
ACTH receptor. The ACTH receptor coding region, as deter-
mined by PCR of genomic DNA obtained from peripheral
FIG. 1. In vivo plasma cortisol re-
sponses, in patient 1, to 100 g
GnRH iv (A), 10,000 U hCG im (B),
300 U LH im (C), 250 g ACTH im
(D), 10 mg cisapride orally (E), and
10 mg metoclopramide orally (F). A
and C, Solid lines represent plasma
cortisol concentrations, and dashed
lines represent plasma LH concen-
trations.
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leukocytes, was entirely normal in both patients (data not
shown).
Discussion
The ACTH-independent Cushing’s syndrome in both our
patients was based on bilateral adrenal hyperplasia and char-
acterized by in vivo responsiveness of cortisol production to
GnRH, hCG, LH, and 5-HT4 receptor agonists. The cortisol
response to GnRH, hCG, and LH, but not to FSH, as well as
the presence of LH receptor mRNA in adrenal tissue suggest
that LH regulates, at least in part, cortisol production in these
patients directly at the adrenocortical level.
To date, one case has been previously reported of a post-
menopausal woman with a LH/5-HT4 receptor agonist-
responsive Cushing’s syndrome resulting from bilateral ad-
renal hyperplasia (2). This patient was treated with the GnRH
analog leuprolide acetate, resulting in suppression of LH
levels, followed by normalization of cortisol production. This
implies that the cortisol response to LH indeed plays a patho-
genetic role in this form of Cushing’s syndrome, rather than
being an epiphenomenon. This previous patient and our
patient 1 were postmenopausal, which might point to a cer-
tain threshold for plasma LH concentrations to induce hy-
percortisolism. However, patient 2 was premenopausal,
FIG. 2. In vivo plasma cortisol re-
sponses, in patient 2, to 100 g
GnRH iv (A), 10,000 U hCG im (B),
300 U LH im (C), 250 g ACTH im
(D), 10 mg cisapride orally (E), and
10 mg metoclopramide orally (F). A
and C, Solid lines represent plasma
cortisol concentrations, and dashed
lines represent plasma LH concen-
trations.
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which indicates that LH concentrations in the lower range
may also regulate cortisol production in the presence of
adrenal LH receptor expression.
The LH receptor is, in man, predominantly expressed in
gonadal tissues but has also been found in other organs, such
as the uterus, brain, and hypothalamus (12). We demon-
strated LH receptor mRNA in the adrenal tissue of both
patients, suggesting aberrant LH receptor expression. How-
ever, in the adrenal tissues of our two patients with pituitary-
dependent Cushing’s syndrome, we found LH receptor
mRNA as well. This is in accordance with a recent postmor-
tem study showing that normal human adrenal tissue con-
tains both LH receptor mRNA and the LH receptor protein,
located in the zona fasciculata and zona reticularis (13). These
data indicate that the LH receptor may be constitutively
expressed by the adrenal gland. LH-responsive Cushing’s
syndrome may therefore be caused by an up-regulation of
the otherwise weakly expressed LH receptor. Postulated
mechanisms underlying an increased expression of the LH
receptor gene include gene rearrangement, resulting in fu-
sion of the LH receptor gene with an adrenocortical-specific
promotor, and abnormalities in transcription factors or their
coactivators or corepressors, caused by gain- or loss-of-func-
tion mutations (1). Alternatively, a mutation of the LH re-
ceptor may underlie adrenal responsiveness to LH. Future
studies should include measurement of the LH receptor pro-
tein and assessment of the LH receptor DNA sequence in
adrenal tissue from patients with LH-responsive Cushing’s
syndrome and in control adrenal tissue.
There is increasing evidence that LH has regulatory effects
on adrenal steroidogenesis. For instance, hCG, acting via the
LH receptor, stimulates dehydroepiandrosterone sulfate
production by human fetal adrenal cells (14) and induces
cortisol secretion by guinea pig adrenal cells (15). In addition,
in women with the polycystic ovarian syndrome, elevated
LH concentrations coincide with an increased adrenal an-
drogen production (16). Kero et al. (17) examined the effects
of LH on adrenal function, using a transgenic mouse model
with a high constitutive LH production. These bLH-CTP
mice develop polycystic ovaries with increased androgen
and estrogen levels. Interestingly, chronically elevated LH
concentrations in these mice are also accompanied by the
development of bilateral adrenal hyperplasia with a con-
comitantly increased (up to 14-fold) glucocorticoid produc-
tion. In vitro studies showed the presence of LH receptor
mRNA and protein in adrenal tissue of bLH-CTP mice.
Accordingly, hCG induced, in a dose-dependent fashion,
corticosterone production by primary adrenal cells prepared
from these mice. However, elevated LH concentrations are
not the only factor regulating adrenal corticosterone pro-
duction in bLH-CTP mice. First, gonadectomy of nontrans-
genic mice, also leading to elevated LH levels, did not result
in increased corticosterone production. Second, if the female
bLH-CTP mice were gonadectomized, serum corticoste-
rone levels decreased to levels found in nontransgenic mice,
and no adrenal response to hCG was found in vitro. This
TABLE 2. In vitro cortisol responses of cultured adrenal adenoma cells to ACTH, forskolin, cisapride, and metoclopramide (2-h
stimulated cortisol values, as percentage of patient’s own control values)
Test substance Patient 1 Patient 2 Control 1 Control 2
Control 100  2 100  3 100  3 100  4
ACTH
32 pg/ml 134  7a 152  4a 370  15a 162  2a
64 pg/ml 215  7a 190  9a 382  17a 204  8a
132 pg/ml 212  10a 216  5a 376  14a 247  10a
615 pg/ml 235  17a 259  4a 369  21a 291  16a
Forskolin 1 M 308  20a 355  7a 223  10a 204  8a
Cisapride
0.01 M 84  5 90  5 89  1 93  3
0.1 M 92  6 157  7a 101  6 98  4
1 M 96  5 168  11a 109  7 103  7
Metoclopramide
0.1 M 103  4 105  5 77  2 91  3
1 M 95  2 150  5a 114  3 105  2
10 M 98  6 181  8a 92  5 90  2
Adrenocortical adenoma cells were prepared from hyperplastic adrenal glands of two patients with LH-responsive Cushing’s syndrome and
of two control patients with pituitary-dependent Cushing’s syndrome. Data are expressed as mean (n  4)  SEM.
a P  0.01, compared with patient’s own control.
TABLE 3. In vitro cortisol responses of cultured adrenal adenoma
cells to GnRH, LH, hCG, and FSH (2-h stimulated cortisol values,
as percentage of patient’s own control values)
Test substance Patient 1 Patient 2 Control 1 Control 2
Control 100  2 100  3 100  3 100  4
GnRH
0.1 M 93  4 93  5 90  2 107  4
1 M 93  6 93  7 97  4 109  2
LH
10 mIU/ml 80  2 101  6 88  5
50 mIU/ml 89  5 101  1 90  4
100 mIU/ml 94  4 81  4 92  4 92  9
1000 mIU/ml 92  5 110  5 101  5 103  4
hCG
10 mIU/ml 92  9 93  3 105  6
50 mIU/ml 91  3 90  3 98  2
100 mIU/ml 96  6 122  6a 100  9 101  4
1000 mIU/ml 98  5 145  8a 102  6 103  5
FSH
10 mIU/ml 102  5 108  4 109  2
50 mIU/ml 98  4 103  6 98  4 104  4
100 mIU/ml 105  6 99  6 101  5 111  5
Adrenocortical adenoma cells were prepared from hyperplastic ad-
renal glands of two patients with LH-responsive Cushing’s syndrome
and of two control patients with pituitary-dependent Cushing’s syn-
drome. Data are expressed as mean (n  4)  SEM.
a P  0.05, compared with patient’s own control.
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implies that a gonadal factor derived from the dysfunctional
ovaries is involved in LH-mediated corticosterone produc-
tion in bLH-CTP mice. In this respect, it was postulated that
increased estrogen levels induce PRL secretion (17). PRL, in
turn, is known to induce LH receptor expression in rodents.
In our two patients, serum PRL levels were normal.
Another experimental animal model involves neutered
ferrets. Hyperadrenocorticism, based on adrenal adenoma or
hyperplasia, is a common finding in gonadectomized ferrets
(18). GnRH stimulation in these ferrets results in an increased
adrenal steroid hormone production, and LH receptors have
been demonstrated immunohistochemically in adrenal tis-
sue of neutered ferrets (N. J. Schoemaker, personal commu-
nication). Thus, the gonadectomy-induced increase in LH
release may lead to adrenal LH receptor expression and
LH-responsive steroidogenesis. Indeed, hyperadrenocorti-
coid ferrets can successfully be treated with leuprolide ace-
tate (19). Interestingly, both our patients and the patient
described by Lacroix et al. (2) had undergone a hysterectomy.
However, only the patient reported by Lacroix et al. had also
undergone a bilateral oophorectomy; she was treated though
with estrogen-replacement therapy.
Although we found a profound cortisol response to LH
(agonists) in vivo in our patients, in vitro, only high dosages
of hCG induced a significant increase in cortisol production
by adrenal cells obtained from patient 2. Considering the low
LH receptor mRNA content, this may be explained by a low
LH receptor density. Further, it cannot be excluded that only
a fraction of the adrenals obtained from patient 1, perhaps
one or several nodules, was LH responsive, although the
major part of the adrenals was homogenized before the cells
were brought into culture. Alternatively, LH may interact
with additional factors in the regulation of adrenal cortisol
production, not present in the in vitro setting of dispersed
cells in which part of the in vivo existing interactions are lost.
First, based on the studies with bLH-CTP mice, an ovarian
factor may be involved that may influence LH receptor ex-
pression. Incubation with estradiol, activin, or inhibin, how-
ever, did not influence cortisol response. Future studies
should include coincubation of adrenal cells with LH and
ovarian hormones.
Second, the effect of LH on adrenal steroidogenesis may
be potentiated by or mediated via serotonin. It is intriguing
that the LH-responsive Cushing’s syndrome in both the pre-
viously described patient (2) and in our two patients is as-
sociated with an in vivo cortisol response to 5-HT4 receptor
agonists. In addition, Lacroix and co-workers (20) described
two patients with subclinical Cushing’s syndrome and bi-
lateral adrenal hyperplasia who also showed an in vivo cor-
tisol response to hCG and 5-HT4 receptor agonists. In the
adrenal gland, serotonin is produced by mast cells that can
regulate steroid hormone production in a paracrine manner
(21, 22). Serotonin stimulates aldosterone secretion via acti-
vation of the 5-HT4 receptor, which is expressed in the zona
glomerulosa but also, to a lesser extent, in the zona fascicu-
lata (21). In healthy subjects, 5-HT4 receptor agonists induce
a rise in aldosterone but not in cortisol levels (21). Locally
produced serotonin may be a permissive factor for LH-
induced cortisol secretion. It might also be speculated that
LH induces intraadrenal serotonin release. On the other
hand, 5-HT4 receptor agonists, by themselves, were also ca-
pable of inducing cortisol production, which suggests an
altered functional coupling between the 5-HT4 receptor and
cortisol secretion and/or an increased 5-HT4 receptor ex-
pression by cortisol-secreting cells. Serotonin may also in-
fluence cortisol production indirectly via induction of in-
traadrenal IL-6 release (21). Similar to the responses to LH,
however, we found a discrepancy between the in vivo and in
vitro responses to 5-HT4 receptor agonists; only in patient 2,
an effect of cisapride and metoclopramide was demonstrated
in vitro. Therefore, an interaction between LH and serotonin
and between their (post) receptors (effects) in the regulation
of cortisol production seems likely. The exact mechanism,
though, is presently unknown.
FIG. 3. Human LH receptor mRNA ex-
pression in adrenal tissue. Using RNase
protection assay, LH receptor mRNA
expression was determined in adrenal
tissue obtained from two control pa-
tients (Co1 and Co2) with pituitary-
dependent Cushing’s syndrome and
from two patients with LH-responsive
Cushing syndrome (Pt1 and Pt2) based
on bilateral adrenal hyperplasia. As
control, the LH receptor-expressing
K15 cell line was used. In the top of the
figures, the autoradiograph of the spe-
cific bands are shown. The bars indicate
the quantitative analysis of the bands,
expressed as the ratio of LH receptor to
-actin.
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One of the proposed mechanisms of a predominant ad-
renal response to stimuli other than ACTH is a defect in the
ACTH signal cascade, e.g. caused by a mutation of the ACTH
receptor (1). The ACTH receptor coding region, as deter-
mined in genomic DNA, was, however, entirely normal in
both patients. Indeed, despite the regulatory potential of LH
and 5-HT4 receptor agonists on cortisol production in our
patients, their adrenals were still responsive to ACTH, both
in vivo and in vitro.
In conclusion, LH-responsive Cushing’s syndrome asso-
ciated with bilateral adrenal hyperplasia may result from
aberrant or increased adrenal LH receptor expression. This
variant is further characterized by adrenal responsiveness to
5-HT4 receptor agonists, possibly pointing to an interaction
between LH and serotonin in the regulation of cortisol
secretion.
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